| Pronunciation |
 (imi
GLOO ser
ase) |
 |
| U.S. Brand Names |
| Cerezyme® |
|
| Generic Available |
|
No |
|
| Pharmacological Index |
|
Enzyme |
|
| Use |
|
Long-term enzyme replacement therapy for patients with Type 1 Gaucher's disease |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Hypersensitivity to imiglucerase or any component |
|
| Adverse Reactions |
|
1% to 10%: Central nervous system: Headache, dizziness Dermatologic: Rash, pruritus Gastrointestinal: Nausea, abdominal discomfort Genitourinary: Decreased urinary frequency |
|
| Usual Dosage |
|
I.V.: 2.5 units/kg 3 times a week up to as much as 60 units/kg administered as frequently as once a week or as infrequently as every 4 weeks; 60 units/kg administered every 2 weeks is the most common dose |
|
| Mental Health: Effects on Mental Status |
|
May cause dizziness |
|
| Mental Health: Effects on Psychiatric Treatment |
|
None reported |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Dosage Forms |
|
Powder for injection, preservative free (lyophilized): 212 units [equivalent to a withdrawal dose of 200 units] |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
